MétaCan
Menu
Back to cohort
Record W2910356129 · doi:10.1136/jnnp-2018-319831

Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis

2019· article· en· W2910356129 on OpenAlexaff
Tomáš Kalinčík, Eva Havrdová, Dana Horáková, Guillermo Izquierdo, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Marco Onofrj, Alessandra Lugaresi, Serkan Özakbaş, Ludwig Kappos, Jens Kühle, Murat Terzi, Jeannette Lechner‐Scott, Cavit Boz, François Grand’Maison, Julie Prévost, Patrizia Sola, Diana Ferraro, Franco Granella, María Trojano, Roberto Bergamaschi, Eugenio Pucci, Recai Türkoğlu, Pamela McCombe, Vincent Van Pesch, Bart Van Wijmeersch, Claudio Solaro, Cristina Ramo‐Tello, Mark Slee, Raed Alroughani, Bassem Yamout, Vahid Shaygannejad, Daniele Spitaleri, José Luis Sánchez-Menoyo, Radek Ampapa, Suzanne Hodgkinson, Rana Karabudak, Ernest Butler, Steve Vucic, Vilija Jokubaitis, Tim Spelman, Helmut Butzkueven

Bibliographic record

VenueJournal of Neurology Neurosurgery & Psychiatry · 2019
Typearticle
Languageen
FieldMedicine
TopicMultiple Sclerosis Research Studies
Canadian institutionsCegep de Saint JeromeCentre intégré de santé et de services sociaux de Chaudière-AppalachesUniversité de MontréalHôpital Notre-Dame
FundersNational Health and Medical Research CouncilTeva Pharmaceutical IndustriesBiogenSanofiMedical Research CouncilSanofi Genzyme
KeywordsTeriflunomideFingolimodDimethyl fumarateMedicineMultiple sclerosisDiscontinuationInternal medicinePharmacologyImmunology

Abstract

fetched live from OpenAlex

OBJECTIVE: Oral immunotherapies have become a standard treatment in relapsing-remitting multiple sclerosis. Direct comparison of their effect on relapse and disability is needed. METHODS: We identified all patients with relapsing-remitting multiple sclerosis treated with teriflunomide, dimethyl fumarate or fingolimod, with minimum 3-month treatment persistence and disability follow-up in the global MSBase cohort study. Patients were matched using propensity scores. Three pairwise analyses compared annualised relapse rates and hazards of disability accumulation, disability improvement and treatment discontinuation (analysed with negative binomial models and weighted conditional survival models, with pairwise censoring). RESULTS: The eligible cohorts consisted of 614 (teriflunomide), 782 (dimethyl fumarate) or 2332 (fingolimod) patients, followed over the median of 2.5 years. Annualised relapse rates were lower on fingolimod compared with teriflunomide (0.18 vs 0.24; p=0.05) and dimethyl fumarate (0.20 vs 0.26; p=0.01) and similar on dimethyl fumarate and teriflunomide (0.19 vs 0.22; p=0.55). No differences in disability accumulation (p≥0.59) or improvement (p≥0.14) were found between the therapies. In patients with ≥3-month treatment persistence, subsequent discontinuations were less likely on fingolimod than teriflunomide and dimethyl fumarate (p<0.001). Discontinuation rates on teriflunomide and dimethyl fumarate were similar (p=0.68). CONCLUSION: The effect of fingolimod on relapse frequency was superior to teriflunomide and dimethyl fumarate. The effect of the three oral therapies on disability outcomes was similar during the initial 2.5 years on treatment. Persistence on fingolimod was superior to the two comparator drugs.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.190
Threshold uncertainty score0.869

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.078
GPT teacher head0.343
Teacher spread0.266 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations88
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Neurology Neurosurgery & PsychiatrySame topicMultiple Sclerosis Research StudiesFrench-language works237,207